Catalyst Event

Merck and Co Inc (MRK) · Other

From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)

4/28/2026, 12:00:00 AM

OtherSentiment: Neutral

The FDA has set a PDUFA target action date of April 28, 2026, for its review of the New Drug Application for doravirine/islatravir, an investigational HIV treatment. Approval typically impacts price by 5-10%, scheduled.

Korean Translation

미국 FDA가 HIV 치료 후보 약물인 도라비린/이슬라트라비르의 신약 허가 신청(NDA)에 대한 PDUFA 목표일을 2026년 4월 28일로 지정함. 신약 승인은 보통 5-10%의 주가 영향을 미칠 것으로 예상됨, 예정됨.

Related Recent Events

View Full Timeline